Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran.
Angiology. 2013 Jan;64(1):40-5. doi: 10.1177/0003319711435149. Epub 2012 Feb 3.
The metabolic syndrome (MetS) is characterized by constellation of clinical and biochemical features that increase the risk of cardiovascular disease. Neuropeptide Y (NPY) is a neurotransmitter and enhances the development of obesity and other aspects of MetS. We determined the association between NPY Leu7Pro polymorphism and features of MetS in Iranian patients with coronary artery disease (CAD). A total of 550 patients with CAD including individuals with (n = 184) and without MetS (n = 366) were genotyped by polymerase chain reaction-restriction fragment length polymorphism. A significantly higher frequency of the Leu7Pro polymorphism was found in patients with MetS compared with the non-MetS patients (P = .001). Furthermore, there was a significant difference in Pro7 frequency between diabetics versus nondiabetics (P = .005), dyslipidemic versus nondyslipidemic (P = .04), and obese versus nonobese (P = .001) in this population. Leu7Pro polymorphism is associated with the MetS in patients with CAD.
代谢综合征（MetS）的特征是一系列临床和生化特征，这些特征增加了心血管疾病的风险。神经肽 Y（NPY）是一种神经递质，可增强肥胖和 MetS 的其他方面的发展。我们确定了 NPY Leu7Pro 多态性与伊朗冠心病（CAD）患者 MetS 特征之间的关联。通过聚合酶链反应-限制性片段长度多态性对 550 例 CAD 患者（包括合并 MetS 的患者（n = 184）和不合并 MetS 的患者（n = 366））进行了基因分型。与非 MetS 患者相比，MetS 患者的 Leu7Pro 多态性频率明显更高（P =.001）。此外，在该人群中，糖尿病患者与非糖尿病患者之间（P =.005）、血脂异常患者与非血脂异常患者之间（P =.04）、肥胖患者与非肥胖患者之间（P =.001），Pro7 频率存在显著差异。Leu7Pro 多态性与 CAD 患者的 MetS 有关。
